Boston University
Modeling myasthenia gravis with an optogenetic neuromuscular platform: evaluation of a new drug
Abstract
dc:description.abstractMyasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness caused by deterioration of the neuromuscular junction (NMJ). MG autoantibodies typically target acetylcholine receptor (AChR) proteins in the NMJ, blocking their function, causing their internalization and turnover, or damaging the cell through the complement protein cascade. The purpose of this study is to recapitulate the pathophysiology of MG using an in vitro human 3D optogenetic NMJ model, evaluate functional changes due to MG patient serum, and to test the efficacy of a complement protein inhibitor. Understanding the morphological and functional changes caused by various patient sera and their antibodies will assist in evaluating the inhibitor and help design future treatments for MG. This study showed that MG patient sera decreased NMJ function significantly in the model and demonstrated that the complement inhibitor was effective at protecting NMJ function when used prophylactically.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2022
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Liberman, Martin
- Advisors dc:contributor.advisor
-
- Chen, Christopher
- Vunjak-Novakovic, Gordana
Subjects
dc:subject × 1Rights
dc:rights- Statement dc:rights
-
- Attribution 4.0 International
- Licence dc:rights.uri
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/45594